Al-Madina Pharma makes trading debut today

Al-Madina Pharmaceuticals Limited will make the share trading debut today on the SME platform of the stock exchanges.

The company is classified as belonging to the ‘Pharmaceuticals & Chemicals’ sector and has been given the trading code "AMPL" and DSE company code "68004" at Dhaka Stock Exchange (DSE).

According to its unaudited second quarterly financial statements, the company recorded a profit after tax of Tk 1.7 crore, and a basic earnings per share (EPS) of Tk 1.13 for the period of July-December 2022.

This is in comparison to a profit after tax of Tk 1.84 crore and a basic EPS of Tk 1.24 for the same period in the previous year, July-December 2021.

However, the post-QIO (Qualified Institutional Offering) basic EPS for the current period of July-December 2022 is projected to be Tk 0.85.

The weighted average paid-up number of shares before the QIO for July-December 2022 was 1.5 crore, compared to 1.49 crore for the same period in the previous year.

However, after the QIO, the paid-up number of shares is expected to be 2 crore. The pre-QIO net asset value (NAV) per share, considering both with and Without Revaluation Surplus and the pre-QIO paid-up shares, was Tk 22.78 and Tk 13.75 respectively as of December 31, 2022.

On the same date, considering the post-QIO paid-up shares, the respective values would be Tk 19.65 and Tk 12.83.

The qualified investor offer (QIO) for Al-Madina Pharmaceuticals shares began on May 7, with the company aiming to raise Tk 5 crore through the fixed price method. The Bangladesh Securities and Exchange Commission (BSEC) had previously granted approval to Al-Madina Pharmaceuticals on February 1 to raise funds via the SME platform.

To facilitate its fundraising efforts, Al-Madina Pharmaceuticals will issue 50 lakh ordinary shares, each with a face value of Tk 10. The generated proceeds will be utilized for business expansion and debt repayment, aligning with the company's growth strategy.

Prime Bank Investment Ltd. has been appointed as the issue manager for the QIO of Al-Madina Pharmaceuticals, overseeing the process and ensuring its smooth execution.

As per BSEC regulations, Al-Madina Pharma will be prohibited from declaring any stock dividends for a period of three years from the date of its listing on the stock market.